May 24 2022 Positive Phase II results for PTR-01
BridgeBio Pharma and Phoenix Tissue Repair reported positive results from a phase II trial of PTR-01, an intravenously-administered recombinant collagen VII protein replacement therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB).
In the trial, PTR-01 was administered once per week for four weeks and then on alternate weeks for a further 14 weeks. The open-label study reported improved wound healing and, the five patients that completed the study, reported a decrease in pain
Read the press release from BridgeBio Pharma.